<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puspa SD. Solihah</style></author><author><style face="normal" font="default" size="100%">Ellisa Clara Pasaribu</style></author><author><style face="normal" font="default" size="100%">Fahmi Ahsanul Haq</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Network Pharmacology-based Prediction and In Vivo Validation of Red Ginger and Turmeric Extract Combinations against Hypercoagulability in Isoproterenol-Induced Rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anticoagulant</style></keyword><keyword><style  face="normal" font="default" size="100%">Coagulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Curcuma longa</style></keyword><keyword><style  face="normal" font="default" size="100%">Isoproterenol</style></keyword><keyword><style  face="normal" font="default" size="100%">Network pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Zingiber officinale rubrum</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2026</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">139-149</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Myocardial infarction is a critical cardiovascular condition often preceded by a hypercoagulable state. Red ginger (&lt;em&gt;Zingiber officinale&lt;/em&gt; var. &lt;em&gt;rubrum&lt;/em&gt;, ZOR) and turmeric (&lt;em&gt;Curcuma longa&lt;/em&gt; L., CL) are recognized for their anticoagulant properties, yet their multi-target pharmacological interactions remain poorly understood. This study aimed to evaluate the anticoagulant potential of ZOR and CL combinations using an integrated network pharmacology and&lt;em&gt; in vivo&lt;/em&gt; approach. &lt;strong&gt;Methods: &lt;/strong&gt;Network pharmacology analysis was employed to predict potential molecular targets of ZOR and CL bioactive compounds. For &lt;em&gt;in vivo&lt;/em&gt; validation, rats were treated with single extracts (300 mg/kg bw) or combinations (ratios 1:1, 1:3, 3:1), followed by isoproterenol-induced hypercoagulability. Anticoagulant activity was assessed by measuring Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT).&lt;strong&gt; Results:&lt;/strong&gt; Network pharmacology identified 10 key hub proteins, including STAT3, AKT1, and MTOR, indicating a multi-target mechanism. &lt;em&gt;In vivo&lt;/em&gt;, isoproterenol effectively induced hypercoagulability. While ZOR (300 mg/kg BW) showed the highest individual potency, all combinations significantly prolonged PT and aPTT (p &amp;lt; 0.05). Based on Chou-Talalay analysis, the interaction was dose-dependent; PT showed nearly additive to synergistic effects (CI: 0.86– 1.07), whereas aPTT exhibited antagonistic trends (CI: 1.06–1.50) at higher ZOR ratios. Consequently, combination effects remained stable without exceeding the most potent single dose. &lt;strong&gt;Conclusion: &lt;/strong&gt;The ZOR and CL combination provides a consistent anticoagulant response through additive interactions, likely mediated by the modulation of the AKT/mTOR signaling axis and coagulation factors. This integration offers a promising, safer multi-target strategy for preventing thrombotic events in myocardial infarction.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">139</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Puspa SD. Solihah&lt;sup&gt;1*&lt;/sup&gt;, Ellisa Clara Pasaribu&lt;sup&gt;1&lt;/sup&gt;, Fahmi Ahsanul Haq&lt;sup&gt;1&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Faculty of Pharmacy, Universitas Jenderal Achmad Yani (UNJANI), Jalan Terusan Jenderal Sudirman, Cimahi, West Java, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bassam A. Hazae</style></author><author><style face="normal" font="default" size="100%">Yetti Hernaningsih</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author><author><style face="normal" font="default" size="100%">Fatima Albadwi</style></author><author><style face="normal" font="default" size="100%">Nastasya Nunki</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Abnormalities in Hemostatic Parameters Related to Hemodialysis in End-stage Kidney Pathology: A Narrative Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Coagulation</style></keyword><keyword><style  face="normal" font="default" size="100%">End-stage Kidney Disease (ESKD)</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemodialysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemostasis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1223-1230</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Chronic kidney disease (CKD) is a progressively prevalent global health issue. During the initial phases of the condition, CKD is commonly linked to a tendency for excessive blood clotting. While in the end-stage of disease, patients undergoing hemodialysis have a multitude of hemostatic abnormalities. These include prolonged bleeding time, altered platelet count, prolonged PT and aPTT, elevated FDPs and D-dimer, dysregulated vWF activity, and abnormal thrombin generation. These changes result from a combination of uremic toxicity, endothelial dysfunction, inflammatory states, and the effects of the hemodialysis procedure itself. Understanding these mechanisms is crucial for managing and mitigating the bleeding and thrombotic risks in this patient population. This review aims to systematically investigate the effects of hemodialysis on key hemostasis parameters in CKD patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">1223</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Bassam A. Hazae&lt;sup&gt;1&lt;/sup&gt;, Yetti Hernaningsih&lt;sup&gt;2,3,4*&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;2,3,4,5&lt;/sup&gt;, Fatima Albadwi&lt;sup&gt;6&lt;/sup&gt;, Nastasya Nunki&lt;sup&gt;1,7&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Laboratory Medicine Study Interest, Master Program of Basic Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;²Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Dr. Soetomo General Academic Hospital, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;⁴Postgraduate School of Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;6&lt;/sup&gt;Master student, Biotechnology and Bioengineering, East China University of Science and Technology, Shanghai, CHINA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;7&lt;/sup&gt;Department of Medical Laboratory Technology, Faculty of Health, Universitas Nahdlatul Ulama Surabaya, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>